Singapore markets close in 4 hours 15 minutes

UroGen Pharma Ltd. (0XOD.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
17.11+0.45 (+2.69%)
At close: 05:44PM BST
Full screen
Previous close16.66
Open0.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range0.00 - 0.00
52-week range
Volume18
Avg. volume457
Market cap239.448M
Beta (5Y monthly)1.12
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

    PRINCETON, N.J., June 18, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ordinary share, and, to certain investors in lieu of issuing ordinary shares, pre-funded warrants to purchase 1,142,857 ordinary shares at a purchase price of $17.499 per pre

  • GlobeNewswire

    UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

    PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell its ordinary shares and pre-funded warrants. In connection with the proposed offering, UroGen also expects to grant the underwriters a 30-day option to purch

  • Business Wire

    UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

    PRINCETON, N.J., June 13, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced 82.3% (95% CI, 75.9%, 87.1%) 12-month duration of response (DOR) data by Kaplan-Meier estimate (n=108) from its Phase 3 ENVISION trial in patients who achieved complete response (CR) at three months after the first instillation of investigational drug UGN-102 (mitomycin) for intravesical solut